CN113577380A - 一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 - Google Patents
一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 Download PDFInfo
- Publication number
- CN113577380A CN113577380A CN202110883656.2A CN202110883656A CN113577380A CN 113577380 A CN113577380 A CN 113577380A CN 202110883656 A CN202110883656 A CN 202110883656A CN 113577380 A CN113577380 A CN 113577380A
- Authority
- CN
- China
- Prior art keywords
- solution
- stirring
- aqueous solution
- sample
- gamma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003519 biomedical and dental material Substances 0.000 title claims abstract description 15
- 208000029549 Muscle injury Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000007864 aqueous solution Substances 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 36
- 238000003756 stirring Methods 0.000 claims abstract description 35
- 239000004220 glutamic acid Substances 0.000 claims abstract description 27
- 229920001661 Chitosan Polymers 0.000 claims abstract description 23
- 239000000017 hydrogel Substances 0.000 claims abstract description 23
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007853 buffer solution Substances 0.000 claims abstract description 12
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 11
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims abstract description 9
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- 229910021538 borax Inorganic materials 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- 229960001149 dopamine hydrochloride Drugs 0.000 claims abstract description 9
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 9
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 9
- 239000011259 mixed solution Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 6
- 238000000520 microinjection Methods 0.000 claims description 5
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 229960000292 pectin Drugs 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 12
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052796 boron Inorganic materials 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 239000002861 polymer material Substances 0.000 abstract description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract description 2
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000002340 cardiotoxin Substances 0.000 description 1
- 231100000677 cardiotoxin Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于高分子材料技术领域,具体涉及一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法。该材料通过以下方法制备而成:将聚多糖于室温下搅拌溶解于去离子水中,依次加入硼砂,N‑羟基琥珀酰亚胺,搅拌后加入多巴胺盐酸盐,处理后得样品;将样品加水搅拌得样品的水溶液,量取H2O2水溶液、聚γ‑谷氨酸/壳聚糖溶液和磷酸缓冲溶液,混合均匀后,边振荡边向其中加入样品的水溶液,得到的无色透明的混合溶液变为棕色,即得到可注射黏附性水凝胶。本发明制备的负载硼的γ‑PGA‑CS水凝胶,有利于分化的肌管的形成,这对于正确创建肌管是必不可少的,且刺激性小,大大的提高了生物利用度,降低了药物毒性。
Description
技术领域
本发明属于高分子材料技术领域,具体涉及一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法。
背景技术
近年来,随着前沿学科的迅猛发展和科学技术的飞速发展,新型生物医用材料被广泛应用到军事材料、生物医用材料、通讯材料等各个方面。新型生物医用材料继承了天然生物材料的独特的结构和优越的性能,人们志在制备出具备不同功用的新型新型生物医用材料。目前,对于新型生物医用材料的研究无论在结构还是功能方面,都已经取得了较为显著的成果,而水凝胶也成为了受益者之一。水凝胶是一类具有三维立体的高分子网状结构的材料,亲疏水基团并存的结构使其既具有流动性,又具一定的力学强度。根据原料来源的不同,可以将水凝胶分为天然水凝胶和合成水凝胶。天然水凝胶由于其特有的生物学特性(生物相容性、生物可降解性等)和与细胞外基质的相似性而常被用于细胞和组织工程等方面,其中的一些天然生物高分子主要是胶原蛋白、纤维蛋白、透明质酸钠(HA)、明胶、壳聚糖、纤维素、藻酸盐和琼脂糖等物质,其与生物体的密切关系使其在人工组织、伤口敷料、药物缓释以及化学传感器等方面都具有广阔的应用前景。
随着人们生活质量和运动水平的不断提高,肌腱、神经等组织的损伤问题也越来越多,目前所存在的治疗手段主要有手术治疗和保守治疗,但都存在或大或小的风险,因此我们急需一种生物相容性好且具有黏附性的材料来帮助其修复并解决一些问题,于是仿生的黏附性水凝胶因其独特的生化功能与物理特性在众多的具有医用功能的聚合物材料中脱颖而出,在不损失材料本身特性的基础上仍能赋予其更多新型功能将使这种材料在生物医学等方面发挥重要作用。
目前多数硼载体其靶向性差,且生物利用度低,药物的毒副作用较高。因此,研发一种新型的生物医用材料成为了亟待解决的问题。
发明内容
针对现有技术中存在的问题,本发明提供了一种用于治疗和恢复肌肉损伤的新型生物医用材料。
本发明还提供了一种用于治疗和恢复肌肉损伤的新型生物医用材料的制备方法。
本发明为了实现上述目的所采用的技术方案为:
本发明提供了一种用于治疗和恢复肌肉损伤的新型生物医用材料的制备方法,包括以下步骤:
1)将聚多糖于室温下搅拌溶解于去离子水中,依次加入硼砂,N-羟基琥珀酰亚胺,搅拌后加入多巴胺盐酸盐,调节体系的pH,通氮气,密闭搅拌,然后在通氮气的条件渗析,渗析后的聚合物溶液用冻干机冻干得到蓬松多孔的样品;
2)将步骤1)得到的样品加水搅拌得样品的水溶液,配置H2O2水溶液,聚γ-谷氨酸/壳聚糖溶液,磷酸缓冲溶液,量取H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液,混合均匀后,边振荡边向其中加入样品的水溶液,得到的无色透明的混合溶液变为棕色,即得到可注射黏附性水凝胶。
进一步的,所述步骤1),具体过程为:1.0~4.0g聚多糖于室温下搅拌溶解在150~300mL去离子水中,依次加入硼砂1.4260~5.7038g,N-羟基琥珀酰亚胺0.8561~3.4244g,搅拌30~50分钟后加入多巴胺盐酸盐0.9404~3.7617g,用浓度为0.1~0.4mol/L的盐酸调节体系的pH为4.6~5.0之间,通氮气5~10分钟,密闭搅拌20~30小时,然后在通氮气的条件下用分子量为8000~14000的渗析袋渗析2~3天,换4~5次水,渗析后的聚合物溶液用冻干机冻干2~3天后得到蓬松多孔的样品。
上述聚多糖的分子量是200~700kDa;所述聚多糖为透明质酸钠、海藻酸钠或果胶。
进一步的,步骤2)中,所述样品的水溶液的质量浓度为1.0~2.0wt%;所述H2O2水溶液的浓度为2~20mM;所述聚γ-谷氨酸/壳聚糖溶液的浓度为20~200u/mL;所述磷酸缓冲液的pH=5~8。
上述H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液的体积比为1:1:1;所述每1-2mL样品的水溶液中加入H2O2水溶液400~800μL。
本发明所使用的聚γ-谷氨酸/壳聚糖通过以下方法制备而成:将10mL,2g/L的聚γ-谷氨酸溶液用微量注射泵按照 6 mL/h 的速率滴加到50 mL,pH=6的质量分数为3%的CS水溶液中,边加边搅拌并超声10min,透析3h除去未结合的小分子聚合物,得聚γ-谷氨酸/壳聚糖溶液。
本发明还提供了一种利用上述制备方法制备的生物医用材料。
本发明还提供了一种上述生物医用材料在制备用于治疗和恢复肌肉损伤的可注射粘附性水凝胶中的应用。
本发明制备的生物材料将硼负载到水凝胶中,提高硼的负载率的同时,能够有效的控制硼的释放。当释放时,刺激整联蛋白,从而形成正确的组织。同时,硼能够在未分化的肌肉细胞中诱导更多的粘连,而未分化的肌肉细胞是受伤后参与肌肉再生的细胞,最终有利于分化的肌管的形成,这对于正确创建肌管是必不可少的。
本发明的有益效果为:
(1)本发明制备的水凝胶原料来源广,生物相容性好,无毒,有利于产品的商品化。
(2)制备操作过程简便,绿色无污染。
(3)本发明制备的负载硼的γ- PGA-CS水凝胶,有利于分化的肌管的形成,这对于正确创建肌管是必不可少的,且刺激性小,大大的提高了生物利用度,降低了药物毒性。
具体实施方式
下面通过具体的实施例对本发明的技术方案作进一步的解释和说明。
实施例1
1)1g透明质酸于室温下搅拌溶解在150mL去离子水中,依次加入硼砂1.4260g,N-羟基琥珀酰亚胺0.8561g,搅拌30分钟后加入多巴胺盐酸盐0.9404g,用浓度为0.1mol/L的盐酸调节体系的pH为4.6,通氮气5分钟,密闭搅拌20小时,然后在通氮气的条件下用分子量为8000的渗析袋渗析2天,换4次水,渗析后的聚合物溶液用冻干机冻干2天后得到蓬松多孔的样品;
2)将10mL,2g/L的聚γ-谷氨酸溶液用微量注射泵按照 6 mL/h 的速率滴加到50mL,pH=6的质量分数为3%的CS水溶液中,边加边搅拌并超声10min,透析3h除去未结合的小分子聚合物,得聚γ-谷氨酸/壳聚糖溶液;
3)将步骤1)样品配成1.0wt%的水溶液,配置2mM的H2O2水溶液,20u/mL的聚γ-谷氨酸/壳聚糖溶液,pH=5的磷酸缓冲溶液,分别取H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液各400μL,混合均匀后,边振荡边向其中加入1mL步骤1)样品的水溶液,得到的无色透明的混合溶液在60s的时间内变为棕色,即得到可注射黏附性水凝胶。
实施例2
1)2g海藻酸钠于室温下搅拌溶解在200mL去离子水中,依次加入硼砂2.4260g,N-羟基琥珀酰亚胺1.8561g,搅拌40分钟后加入多巴胺盐酸盐1.9404g,用浓度为0.2mol/L的盐酸调节体系的pH为4.8,通氮气6分钟,密闭搅拌25小时,然后在通氮气的条件下用分子量为9000的渗析袋渗析2天,换4次水,渗析后的聚合物溶液用冻干机冻干2天后得到蓬松多孔的样品;
2)将10mL,2g/L的聚γ-谷氨酸溶液用微量注射泵按照 6 mL/h 的速率滴加到50mL,pH=6的质量分数为3%的CS水溶液中,边加边搅拌并超声10min,透析3h除去未结合的小分子聚合物,得聚γ-谷氨酸/壳聚糖溶液;
3)将步骤1)样品配成1.0wt%的水溶液,配置2mM的H2O2水溶液,20u/mL的聚γ-谷氨酸/壳聚糖溶液,pH=5的磷酸缓冲溶液,分别取H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液各400μL,混合均匀后,边振荡边向其中加入1mL步骤1)样品的水溶液,得到的无色透明的混合溶液在60s的时间内变为棕色,即得到可注射黏附性水凝胶。
实施例3
1)3g果胶于室温下搅拌溶解在250mL去离子水中,依次加入硼砂3.4260g,N-羟基琥珀酰亚胺2.8561g,搅拌50分钟后加入多巴胺盐酸盐2.9404g,用浓度为0.4mol/L的盐酸调节体系的pH为5.0,通氮气10分钟,密闭搅拌30小时,然后在通氮气的条件下用分子量为14000的渗析袋渗析3天,换5次水,渗析后的聚合物溶液用冻干机冻干3天后得到蓬松多孔的样品;
2)将10mL,2g/L的聚γ-谷氨酸溶液用微量注射泵按照 6 mL/h 的速率滴加到50mL,pH=6的质量分数为3%的CS水溶液中,边加边搅拌并超声10min,透析3h除去未结合的小分子聚合物,得聚γ-谷氨酸/壳聚糖溶液;
3)将步骤1)样品配成1.0wt%的水溶液,配置2mM的H2O2水溶液,20u/mL的聚γ-谷氨酸/壳聚糖溶液,pH=5的磷酸缓冲溶液,分别取H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液各400μL,混合均匀后,边振荡边向其中加入1mL步骤1)样品的水溶液,得到的无色透明的混合溶液在60s的时间内变为棕色,即得到可注射黏附性水凝胶。
对比例1
1)1g透明质酸于室温下搅拌溶解在150mL去离子水中,依次加入硼砂1.4260g,N-羟基琥珀酰亚胺0.8561g,搅拌30分钟后加入多巴胺盐酸盐0.9404g,用浓度为0.1mol/L的盐酸调节体系的pH为4.6,通氮气5分钟,密闭搅拌20小时,然后在通氮气的条件下用分子量为8000的渗析袋渗析2天,换4次水,渗析后的聚合物溶液用冻干机冻干2天后得到蓬松多孔的样品;
2)将步骤1)样品配成1.0wt%的水溶液,配置2mM的H2O2水溶液,pH=5的磷酸缓冲溶液,分别取H2O2水溶液和磷酸缓冲溶液各400μL,混合均匀后,边振荡边向其中加入1mL步骤1)样品的水溶液,搅拌60s即可。
效果实施例
(一)购置6周龄野生型小鼠,采用心脏毒素诱发肌肉损伤小鼠模型,经评价建模成功后。将建模成功的小鼠注射本发明实施例1和3制备的水凝胶,同时设置对照组,对照组采用对比例1制备的样品,每组6只,将损伤部位注射0.1mL,连续注射3d,分别于7d,21d取3只小鼠进行肌酸激酶检测,同时进行解剖后,观察肌肉组织,具体结果见表1。
肌酸激酶检测用血采用眼眶静脉丛取血方式,离心后检测血清。
表1
通过表1可以看出,模型组的小鼠,肌肉损伤后,在自愈过程中,其肌酸激酶水平同样出现下降,但始终高于本发明制备的凝胶材料,而当仅注射对比例1制备的产品时,其前期能够有效的降低肌酸激酶水平,但其药效时间较短,而本发明制备的凝胶能够有效的修复受伤组织。
Claims (8)
1.一种用于治疗和恢复肌肉损伤的新型生物医用材料的制备方法,其特征在于,包括以下步骤:
1)将聚多糖于室温下搅拌溶解于去离子水中,依次加入硼砂,N-羟基琥珀酰亚胺,搅拌后加入多巴胺盐酸盐,调节体系的pH,通氮气,密闭搅拌,然后在通氮气的条件渗析,渗析后的聚合物溶液用冻干机冻干得到蓬松多孔的样品;
2)将步骤1)得到的样品加水搅拌得样品的水溶液,配置H2O2水溶液,聚γ-谷氨酸/壳聚糖溶液,磷酸缓冲溶液,量取H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液,混合均匀后,边振荡边向其中加入样品的水溶液,得到的无色透明的混合溶液变为棕色,即得到可注射黏附性水凝胶。
2.根据权利要求1所述的制备方法,其特征在于,所述步骤1),具体过程为:1.0~4.0g聚多糖于室温下搅拌溶解在150~300mL去离子水中,依次加入硼砂1.4260~5.7038g,N-羟基琥珀酰亚胺0.8561~3.4244g,搅拌30~50分钟后加入多巴胺盐酸盐0.9404~3.7617g,用浓度为0.1~0.4mol/L的盐酸调节体系的pH为4.6~5.0之间,通氮气5~10分钟,密闭搅拌20~30小时,然后在通氮气的条件下用分子量为8000~14000的渗析袋渗析2~3天,换4~5次水,渗析后的聚合物溶液用冻干机冻干2~3天后得到蓬松多孔的样品。
3.根据权利要求1或2所述的制备方法,其特征在于,所述聚多糖的分子量是200~700kDa;所述聚多糖为透明质酸钠、海藻酸钠或果胶。
4.根据权利要求1所述的制备方法,其特征在于,步骤2)中,所述样品的水溶液的质量浓度为1.0~2.0wt%;所述H2O2水溶液的浓度为2~20mM;所述聚γ-谷氨酸/壳聚糖溶液的浓度为20~200u/mL;所述磷酸缓冲液的pH=5~8。
5.根据权利要求1或4所述的制备方法,其特征在于,所述H2O2水溶液、聚γ-谷氨酸/壳聚糖溶液和磷酸缓冲溶液的体积比为1:1:1;所述每1-2mL样品的水溶液中加入H2O2水溶液400~800μL。
6.根据权利要求5所述的制备方法,其特征在于,所述聚γ-谷氨酸/壳聚糖通过以下方法制备而成:将10mL,2g/L的聚γ-谷氨酸溶液用微量注射泵按照 6 mL/h 的速率滴加到50mL,pH=6的质量分数为3%的CS水溶液中,边加边搅拌并超声10min,透析3h除去未结合的小分子聚合物,得聚γ-谷氨酸/壳聚糖溶液。
7.一种利用权利要求1-6任一项所述的制备方法制备的生物医用材料。
8.一种如权利要求7所述的生物医用材料在制备用于治疗和恢复肌肉损伤的可注射粘附性水凝胶中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110883656.2A CN113577380A (zh) | 2021-08-03 | 2021-08-03 | 一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110883656.2A CN113577380A (zh) | 2021-08-03 | 2021-08-03 | 一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113577380A true CN113577380A (zh) | 2021-11-02 |
Family
ID=78254192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110883656.2A Pending CN113577380A (zh) | 2021-08-03 | 2021-08-03 | 一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113577380A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115554460A (zh) * | 2022-09-26 | 2023-01-03 | 山东万容生物科技有限公司 | 一种多功能湿性敷料及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250890A1 (en) * | 2012-09-19 | 2015-09-10 | Ajou University Industry-Academic Cooperation Foundation | Method for preparing in situ-formed hydrogel using enzyme-immobilized support, and biomedical use thereof |
CN107312193A (zh) * | 2017-06-27 | 2017-11-03 | 吉林大学 | 一种仿生的可注射黏附性水凝胶、制备方法及其在生物方面的应用 |
CN110343352A (zh) * | 2019-07-24 | 2019-10-18 | 天津大学 | 基于过氧化钙/聚合物产氧粒子的双交联水凝胶及其制备方法 |
CN111234264A (zh) * | 2020-01-16 | 2020-06-05 | 西南科技大学 | 负载有双键化多巴胺的kgm水凝胶的制备方法 |
CN112451730A (zh) * | 2020-12-18 | 2021-03-09 | 曲阜师范大学 | 一种快速促进皮肤伤口愈合的水凝胶纱布的制备方法 |
-
2021
- 2021-08-03 CN CN202110883656.2A patent/CN113577380A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150250890A1 (en) * | 2012-09-19 | 2015-09-10 | Ajou University Industry-Academic Cooperation Foundation | Method for preparing in situ-formed hydrogel using enzyme-immobilized support, and biomedical use thereof |
CN107312193A (zh) * | 2017-06-27 | 2017-11-03 | 吉林大学 | 一种仿生的可注射黏附性水凝胶、制备方法及其在生物方面的应用 |
CN110343352A (zh) * | 2019-07-24 | 2019-10-18 | 天津大学 | 基于过氧化钙/聚合物产氧粒子的双交联水凝胶及其制备方法 |
CN111234264A (zh) * | 2020-01-16 | 2020-06-05 | 西南科技大学 | 负载有双键化多巴胺的kgm水凝胶的制备方法 |
CN112451730A (zh) * | 2020-12-18 | 2021-03-09 | 曲阜师范大学 | 一种快速促进皮肤伤口愈合的水凝胶纱布的制备方法 |
Non-Patent Citations (3)
Title |
---|
JESÚS CIRIZA等: "Borax-loaded injectable alginate hydrogels promote muscle regeneration in vivo after an injury", 《MATERIALS SCIENCE AND ENGINEERING: C》 * |
刘欣 等: "《食品酶学》", 31 March 2006, 中国轻工业出版社 * |
潘卫三 等: "《工业药剂学》", 31 December 2019, 中国医药科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115554460A (zh) * | 2022-09-26 | 2023-01-03 | 山东万容生物科技有限公司 | 一种多功能湿性敷料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singh et al. | Biomedical applications of chitin, chitosan, and their derivatives | |
CN106589424A (zh) | 一种注射用交联透明质酸凝胶及其制备方法 | |
CN106492279A (zh) | 一种丝素蛋白‑透明质酸复合凝胶的快速制备方法 | |
CN102380128B (zh) | 羟基磷灰石、透明质酸钠和魔芋葡甘聚糖复合材料及其制备方法 | |
CN111110914B (zh) | 一种促进骨再生的可注射水凝胶及其制备方法 | |
CN107501577B (zh) | 一种可降解原位凝胶的制备方法 | |
CN105713106A (zh) | 一种海藻酸钠双交联水凝胶及其制备方法与应用 | |
CN114940764B (zh) | 一种水凝胶及其制备方法和应用 | |
KR20100086439A (ko) | 방사선 융합 기술을 이용한 생체조직공학용 베타-글루칸 기반 지지체 및 이의 제조방법 | |
CN112587726B (zh) | 复合水凝胶支架及其制备方法和应用 | |
CN100522247C (zh) | 一种可注射型温敏性壳聚糖/甲基纤维素凝胶及其制备方法 | |
CN111253591A (zh) | 一种双交联透明质酸水凝胶、其制备方法与应用 | |
CN103638562A (zh) | 软骨组织工程支架材料及其制备方法 | |
CN109498838A (zh) | 一种可注射软骨修复水凝胶及其制备方法 | |
CN113429589A (zh) | 甘草酸基pH敏感型缓释水凝胶材料及其制备方法与应用 | |
CN113577380A (zh) | 一种用于治疗和恢复肌肉损伤的新型生物医用材料及其制备方法 | |
CN113278170A (zh) | 一种化学交联透明质酸水凝胶及其制备方法与应用 | |
CN113350567A (zh) | 一种基于胶原的生物相容性高分子敷料 | |
CN104548200A (zh) | 一种制备高支化多糖-丝素水凝胶支架的方法 | |
CN107854729A (zh) | 一种丝素蛋白基自愈合水凝胶及其制备方法 | |
CN201669064U (zh) | 抗凝血复合超滤膜 | |
CN1830420A (zh) | 一种可注射型pH敏感壳聚糖季铵盐水凝胶及其制备方法 | |
CN112812329A (zh) | 巯基改性高分子化合物的水凝胶及其制备方法和用途 | |
CN114099417A (zh) | 中性粒细胞胞外杀菌网络响应性载药凝胶及其制法和使法 | |
US20170291963A1 (en) | Enantiopure or enantioenriched bdde and its use as crosslinking agent in the manufacture of cross-linked products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |
|
RJ01 | Rejection of invention patent application after publication |